Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
The Effective and Safety of Thalidomide in TI
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Xiao-Lin Yin
- Target Recruit Count
- 100
- Registration Number
- NCT03184844
- Locations
- 🇨🇳
NO.3 Hospital of the Chinese People's Liberation Army, Nanjing, Guangxi, China
Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
- Conditions
- Cutaneous LupusSystemic Lupus Erythematosus (SLE)Juvenile SLE
- Interventions
- First Posted Date
- 2017-04-20
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 93
- Registration Number
- NCT03122431
- Locations
- 🇧🇷
Hospital das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil
A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03069326
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)
- Conditions
- Advanced Nsclc
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 232
- Registration Number
- NCT03062800
- Locations
- 🇨🇳
Qilu hospital of Shandong University, Jinan, Shandong, China
Thalidomide Maintenance Treatment in DLBCL
- First Posted Date
- 2017-01-10
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 226
- Registration Number
- NCT03016000
- Locations
- 🇨🇳
Ru Feng, Guangzhou, Guangdong, China
2015-12: a Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 50
- Registration Number
- NCT03004287
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD Patients
- Conditions
- Crohn Disease
- Interventions
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Target Recruit Count
- 90
- Registration Number
- NCT02998827
The Effective and Safety of Thalidomide in NTDT
- First Posted Date
- 2016-12-16
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Xiao-Lin Yin
- Target Recruit Count
- 30
- Registration Number
- NCT02995707
- Locations
- 🇨🇳
NO.3 Hospital of the Chinese People's Liberation Army, Nanjing, Guangxi, China
Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT02966522
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Target Recruit Count
- 72
- Registration Number
- NCT02956538
- Locations
- 🇨🇳
Department of Gastroenterology, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.